Notifications can be turned off anytime from settings.
Item(s) Added To cart
Qty.
Something went wrong. Please refresh the page and try again.
Something went wrong. Please refresh the page and try again.
Exchange offer not applicable. New product price is lower than exchange product price
Please check the updated No Cost EMI details on the payment page
Exchange offer is not applicable with this product
Exchange Offer cannot be clubbed with Bajaj Finserv for this product
Product price & seller has been updated as per Bajaj Finserv EMI option
Please apply exchange offer again
Your item has been added to Shortlist.
View AllYour Item has been added to Shopping List
View AllSorry! 3D Qsar in Drug Design: Ligand-Protein Interactions and Molecular Similarity is sold out.
You will be notified when this product will be in stock
About the Authors
Hugo Kubinyi studied chemistry in Vienna, Austria. After his Ph.D. thesis at the Max Planck Institute of Biochemistry in Munich he continued as a PostDoc at the German Cancer Research Centre in Heidelberg. In 1966 he joined Knoll AG, later a subsidiary of BASF AG, and in 1985 he moved to BASF AG. Since 1987, until his retirement in summer 2001, he was responsible for the Molecular Modelling, Protein Crystallography and Drug Design group of BASF, since early 1998 also for Combinatorial Chemistry in the Life Sciences.
He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. From his scientific work resulted five books on QSAR, 3D QSAR, and Drug
Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry) and about 90 publications.
He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry," and member of the Editorial Boards of several scientific journals.
Gerhard MA1/4ller graduated in Organic Chemistry from the University of Frankfurt/Main (Germany) and received his PhD in 1992 at the Technical University of Munich. After two years in the Medicinal Chemistry department of Glaxo Verona (Italy), he joined the central research facility of the Bayer AG, Leverkusen. From 1998 onwards he was project manager of a target family approach in medicinal chemistry. From 2001 to 2003 he headed the chemistry section of Organon's Lead Discovery Unit in Oss (The Netherlands). Since summer 2003, Gerhard MA1/4ller is the chief scientific officer of the Munich-basedbiotech company Axxima Pharmaceuticals AG.
Hans-Dieter HAltje is director of the Institute of Pharmaceutical Chemistry at the Heinrich-Heine-UniversitAt DA1/4sseldorf (Germany) where he also holds the chair of Medicinal Chemistry. His main interest is the molecular mechanism of drug action.
Wolfgang Sippl is Professor of Pharmaceutical Chemistry at the Martin-Luther-University of Halle-Wittenberg (Germany). He is interested in 3D QSAR, molecular docking and molecular dynamics, and their applications in drug design and pharmacokinetics.
Didier Rognan leads the Drug Bioinformatics Group at the Laboratory for Molecular Pharmacochemistry in Illkirch (France). He is mainly interested in all aspects (method development, applications) of protein-based drug design and virtual screening.
Gerd Folkers is Professor of Pharmaceutical Chemistry at the ETH ZA1/4rich (Switzerland). The focus of his research is the molecular interation between drugs and their binding sites.
The images represent actual product though color of the image and product may slightly differ.
Register now to get updates on promotions and
coupons. Or Download App